Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00

By TheFly | March 11, 2026, 6:00 AM

The deal size was increased to $650M in common stock from $500M in common stock. JPMorgan, Jefferies, TD Cowen, Stifel, RBC Capital and William Blair acted as joint book running managers for the offering.

Claim 70% Off TipRanks Premium

Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See the top stocks recommended by analysts >>

Read More on XENE:

Disclaimer & Disclosure Report an Issue

Mentioned In This Article

XENE

-0.20%

Xenon Pharmaceuticals Inc

Latest News

Sep-10	Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow. XENE Barrons.com
Sep-03	Xenon to Present at Wells Fargo Healthcare Conference XENE GlobeNewswire
Aug-28	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
Aug-26	Xenon to Highlight Phase 3 X-TOLE2 Clinical Data and Rational Polytherapy Potential for Azetukalner at EEC 2026 XENE +5.58% GlobeNewswire
Aug-07	Xenon Pharmaceuticals Inc (XENE) (Q2 2026) Earnings Call Highlights: Advancing Azetukalner ... XENE GuruFocus.com
Aug-06	Xenon Pharmaceuticals: Q2 Earnings Snapshot XENE Associated Press
Aug-06	Xenon Reports Q2 2026 Financial Results and Provides Business Update XENE GlobeNewswire
Jul-31	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
Jul-30	Xenon to Report Q2 2026 Financial Results on August 6, 2026 XENE GlobeNewswire
Jul-02	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
May-29	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
May-07	Xenon Pharmaceuticals: Q1 Earnings Snapshot XENE Associated Press
May-07	Xenon Reports Q1 2026 Financial Results and Provides Business Update XENE GlobeNewswire
May-01	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) XENE GlobeNewswire
May-01	Three Finalists Announced for the 2026 Bloom Burton Award XENE TMX Newsfile

Xenon Pharmaceuticals 10.5M share Spot Secondary priced at $57.00

Claim 70% Off TipRanks Premium

Mentioned In This Article

Latest News

Upgrade your Finviz experience